These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 75929)

  • 21. Evidence that C5b recognizes and mediates C8 incorporation into the cytolytic complex of complement.
    Stewart JL; Kolb WP; Sodetz JM
    J Immunol; 1987 Sep; 139(6):1960-4. PubMed ID: 3624872
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody-mediated complement activation on nucleated cells. A quantitative analysis of the individual reaction steps.
    Ollert MW; Kadlec JV; David K; Petrella EC; Bredehorst R; Vogel CW
    J Immunol; 1994 Sep; 153(5):2213-21. PubMed ID: 8051421
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human polymorphonuclear leukocytes store large amounts of terminal complement components C7 and C6, which may be released on stimulation.
    Høgåsen AK; Würzner R; Abrahamsen TG; Dierich MP
    J Immunol; 1995 May; 154(9):4734-40. PubMed ID: 7722325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elimination of terminal complement intermediates from the plasma membrane of nucleated cells: the rate of disappearance differs for cells carrying C5b-7 or C5b-8 or a mixture of C5b-8 with a limited number of C5b-9.
    Carney DF; Koski CL; Shin ML
    J Immunol; 1985 Mar; 134(3):1804-9. PubMed ID: 3968432
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transmembrane channel-formation by five complement proteins.
    Müller-Eberhard HJ
    Biochem Soc Symp; 1985; 50():235-46. PubMed ID: 2428370
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Moculating effect of the late-acting components of the complement system on the bactericidal activity of human polymorphonuclear leukocytes on E. coli 0111:B4.
    Tedesco F; Rottini G; Patriarca P
    J Immunol; 1981 Nov; 127(5):1910-5. PubMed ID: 7028865
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Receptors for immunoglobulin and complement on human alveolar macrophages.
    Reynolds HY; Atkinson JP; Newball HH; Frank MM
    J Immunol; 1975 Jun; 114(6):1813-9. PubMed ID: 1127229
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunological responsiveness of frozen-thawed human lymphocytes.
    Strong DM; Woody JN; Factor MA; Ahmed A; Sell KW
    Clin Exp Immunol; 1975 Sep; 21(3):442-55. PubMed ID: 128429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The membrane attack mechanism of complement: photolabeling reveals insertion of terminal proteins into target membrane.
    Hu VW; Esser AF; Podack ER; Wisnieski BJ
    J Immunol; 1981 Jul; 127(1):380-6. PubMed ID: 7240749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. C5b-9 assembly: average binding of one C9 molecule to C5b-8 without poly-C9 formation generates a stable transmembrane pore.
    Bhakdi S; Tranum-Jensen J
    J Immunol; 1986 Apr; 136(8):2999-3005. PubMed ID: 3958488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced reactive lysis of paroxysmal nocturnal hemoglobinuria erythrocytes by C5b-9 does not involve increased C7 binding or cell-bound C3b.
    Rosenfeld SI; Jenkins DE; Leddy JP
    J Immunol; 1985 Jan; 134(1):506-11. PubMed ID: 3964820
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The attack phase of human complement: differentiation between membrane binding and complex formation by the detection of neoantigen expression in situ. A morphometric immunoferritin study.
    Balkarowa-Ständer J; Rother U; Rauterberg EW
    J Immunol; 1981 Sep; 127(3):1089-93. PubMed ID: 7264298
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The release of C5a in complement-activated serum does not require C6.
    Biesecker G; Wagner JL; Hugli TE
    J Immunol; 1989 Aug; 143(4):1228-32. PubMed ID: 2545783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complement lysis of human erythrocytes. Differeing susceptibility of two types of paroxysmal nocturnal hemoglobinuria cells to C5b-9.
    Packman CH; Rosenfeld SI; Jenkins DE; Thiem PA; Leddy JP
    J Clin Invest; 1979 Aug; 64(2):428-33. PubMed ID: 457861
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Studies on the mechanism of bacterial resistance to complement-mediated killing. III. C5b-9 deposits stably on rough and type 7 S. pneumoniae without causing bacterial killing.
    Joiner K; Brown E; Hammer C; Warren K; Frank M
    J Immunol; 1983 Feb; 130(2):845-9. PubMed ID: 6848598
    [TBL] [Abstract][Full Text] [Related]  

  • 36. On the mechanism of cell membrane damage by complement: evidence on insertion of polypeptide chains from C8 and C9 into the lipid bilayer of erythrocytes.
    Hammer CH; Shin ML; Abramovitz AS; Mayer MM
    J Immunol; 1977 Jul; 119(1):1-8. PubMed ID: 559700
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assembly of the membrane attack complex promotes decay of the alternative pathway C3 convertase on Neisseria gonorrhoeae.
    Densen P; McRill CM; Ross SC
    J Immunol; 1988 Dec; 141(11):3902-9. PubMed ID: 3141507
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Leukocyte adherence inhibition to myelin basic protein by cancer patients' T-lymphocytes in association with class II major histocompatibility antigens on monocytes.
    Thomson DM; Halliday WJ; Phelan K
    J Natl Cancer Inst; 1985 Dec; 75(6):995-1003. PubMed ID: 2415744
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The modifications of the final stages of the complement reaction by alkali metal cations.
    Dalmasso AP; Lelchuk R; Giavedoni EB; De Isola ED
    J Immunol; 1975 Jul; 115(1):63-8. PubMed ID: 239058
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Homologous species restriction of the complement-mediated killing of nucleated cells.
    Yamamoto H; Blaas P; Nicholson-Weller A; Hänsch GM
    Immunology; 1990 Aug; 70(4):422-6. PubMed ID: 1697561
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.